ALPS Medical Breakthroughs ETF (SBIO) |
| 50.86 -0.09 (-0.18%) 01-13 15:59 |
| Open: | 50.08 |
| High: | 51.2899 |
| Low: | 50.0236 |
| Volume: | 49,962 |
| Market Cap: | 126(M) |
| PE Ratio: | 0 |
| Exchange: | New York Stock Exchange Arca |
| Industry: | Asset Management |
| Sector: | Financial Services |
| Technical analysis | ||||
 |
||||
| sell | buy | |||
| Resistance 2: | 61.79 |
| Resistance 1: | 52.90 |
| Pivot price: | 51.07 |
| Support 1: | 50.15 |
| Support 2: | 48.45 |
| 52w High: | 52.9 |
| 52w Low: | 22.33 |
The fund employs a "passive management" - or indexing - investment approach designed to track the performance of the underlying index. It will normally invest at least 80% of its net assets in securities that comprise the underlying index. The underlying index is comprised of small and mid-cap stocks of biotechnology companies that have one or more drugs in either Phase II or Phase III of the U.S. Food and Drug Administration clinical trials.
Financials
| EPS | 0.000 |
| Book Value | 0.000 |
| PEG Ratio | 0.00 |
| Gross Profit | 0.000 |
| Profit Margin (%) | 0.00 |
| Operating Margin (%) | 0.00 |
| Return on Assets (ttm) | 0.0 |
| Return on Equity (ttm) | 0.0 |
Company news
Fri, 02 Jan 2026
Why (SBIO) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Wed, 24 Dec 2025
ALPS ETFs in Biotech and Commodities Lead 2025 Gains - ETF Trends
Mon, 22 Dec 2025
The Technical Signals Behind (SBIO) That Institutions Follow - Stock Traders Daily
Mon, 15 Dec 2025
Biotech ETF SBIO Hovers Near Peak on Rally - ETF Trends
Fri, 28 Nov 2025
SBIO: A Shock Biotech Winner In 2025 - Seeking Alpha
Wed, 19 Nov 2025
Biotech Consolidation Could Perk Up, Lift This ETF - ETF Trends
 StockChart iOS |
 StoxlineLite iOS |
StoxlineLite iOS |
 OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |
